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Validation of the EBMT risk score in chronic myeloid
leukemia in Brazil and allogeneic transplant outcome  
The approach to primary treatmentfor patients with newly diagnosedchronic myeloid leukemia (CML)
has changed as a result of the effectiveness
and safety of imatinib mesylate.1-6 This
drug has shown activity in all phases of
CML but the best responses are seen in
the early chronic phase.7-11 The results of
the IRIS study of imatinib alone versus
interferon-α (IFN-α) plus cytarabine (Ara-
C) showed that the chance of preventing
progression to accelerated phase or blast
crisis was 97% in a median time of 18
months for patients receiving imatinib
alone versus 93% for those who received
IFN-α plus Ara-C. This was accompanied
by a significant increase in the number of
patients achieving a major cytogenetic
response (MCR) or a complete cytogenet-
ic response (CCR) to 87% and 76%,
respectively for patients receiving imatinib
versus 34% and 15% for those treated
with IFN-α plus Ara-C.11 However, 20-
30% of newly diagnosed patients receiv-
ing 400 mg/day of imatinib fail to achieve
a good molecular response11 and a small
proportion has undetectable levels of BCR-
ABL transcripts.12 BCR-ABL positive
hematopoietic progenitors persist in the
marrow of patients in CCR, indicating that
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Background and Objectives. The management of chronic myeloid leukemia (CML) has
changed radically since the introduction of imatinib therapy. The decision of whether to
offer a patient a hematopoietic stem cell transplant (HSCT) must be based on the
probability of success of the procedure. The aim of this retrospective analysis of 1,084
CML patients who received an allogeneic HSCT in 10 Brazilian Centers between
February 1983 and March 2003 was to validate the EBMT risk score. 
Design and Methods. The study population comprised 647 (60%) males and 437
(40%) females, with a median age of 32 years old (range 1 - 59); 898 (83%) were in
chronic phase, 146 (13%) were in accelerated phase and 40 (4%) were in blast crisis;
151 (14%)  were younger than 20 years old, 620 (57%) were between 20 and 40 and
313 (29%) were older than 40; 1,025 (94%) received an HLA fully matched sibling
transplant and only 59 (6%) received an unrelated transplant. In 283 cases (26%) a
male recipient received a graft from a female donor. The interval from diagnosis to
transplantation was less than 12 months in 223 (21%) cases and greater in 861
(79%). The overall survival, disease-free survival, transplant-related mortality and
relapse incidence were 49%, 50%, 45% and 25%, respectively. 
Results. Of the 1084 patients, 179 (17%) had a risk score of 0 or 1, 397 (37%) had
a score of 2, 345 (32%) had a score of 3, 135 (12%) had a score of 4 and 28 (2%) a
score of 5 or 6. The overall survival (OS) rate in patients with risk scores 0-1 and 2
was similar (58% and 55%, respectively) but significantly better than that in patients
with scores 3 or more (score 3 - 44%, 4 - 36 % and 5-6 - 27%, respectively) (p<0.001).
Disease-free survival (DFS) and transplant related mortality (TRM) in a patients with a
score of 3 or more were 46% and 49%, respectively and the relapse rate beyond score
5-6 was 77%. Disease status had a negative impact on all outcomes (OS, DFS, TRM,
and relapse). The OS rate for male recipients of a graft from a female donor was 40%
compared to 52% among the other donor-recipient pairs (p=0.004). DFS and TRM were
significant for disease phase and female donor-male recipient (p<0.001 and p<0.003,
respectively). In our experience, age and interval between diagnosis and transplant did
influence OS, DFS, TRM, and relapse rate.
Interpretation and Conclusions. Our results validate the EBMT risk score in the context
of a developing country and confirm its usefulness for making point decisions in the
imatinib era.
Key words: allogeneic hematopoietic stem cell transplantation (HSCT), chronic
myeloid leukemia, EBMT risk scores.
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the malignant progenitor may be suppressed but not
eliminated during imatinib treatment.13 Besides these
considerations, concerns exist regarding the develop-
ment of resistance to imatinib.14-18
Allogeneic hematopoietic stem cell transplantation
(HSCT) results in long-term disease control and may
cure selected patients with CML, depending on the
contribution of the graft-versus-leukemia effect.19-21
Comparisons of survival rates afforded by various
treatments are used to formulate general treatment
policies but the decision on whether or not to offer
an allogeneic HSCT should be based on the probabil-
ity of success using this procedure. Prognostic scores
incorporating patient – and disease–specific variables
can assist this decision-making.22 The European
Blood and Marrow Transplant Group (EBMT)
devised a prognostic score for patients receiving allo-
geneic HSCT based on five variables: donor type,
stage of disease, recipient age, donor-recipient sex
match and interval from diagnosis to transplant. The
different scores resulted in substantially different sur-
vival rates23 and this risk score was recently validated
by the International Bone Marrow Transplant
Registry.22 In the imatinib era and in situations with
limited resources we need information regarding the
best chance to benefit from HSCT. Our aim was to
validate the EBMT risk score in a Brazilian popula-
tion in order to be able to give adequate counseling
and take decisions in the imatinib era.
Design and Methods
This retrospective study is based on data from
1,084 patients who underwent an allogeneic HSCT
for CML from an HLA-identical sibling or unrelated
donor in 10 Brazilian centers between February 1983
and March 2003. The EBMT score was not used as an
eligibility criterion for transplant all the time. No
patients had previously received imatinib. A stan-
dardized questionnaire was provided to each institu-
tion to collect the data, which included details of the
patient’s age and sex, donor sex, stage of disease, his-
tocompatibility, time from diagnosis to transplant
and outcome. The stage of disease was classified
according to International Bone Marrow Transplant
Registry.24 Overall survival and transplant-related
mortality were also recorded for different periods of
time.
EBMT risk-score 
The variables were defined as those used to calcu-
late the original EBMT risk score and categorized as
reported by Gratwohl et al.,:23 age (under 20, between
20-40, over 40 years old); interval from diagnosis to
transplant, (>1 and ≤1year); disease status (chronic,
accelerated or blast crisis); donor-recipient sex match
(female donor for male patient versus other); and
donor type (HLA-identical sibling versus unrelated
donor). The risk-score for an individual patient is
simply the sum of the scores for the risk factors used
to calculate the published EBMT risk score:23 donor
type (0 for HLA-identical sibling donor, 1 for a
matched unrelated donor); disease stage (0 for first
chronic phase, 1 for accelerated phase, 2 for blast cri-
sis or higher chronic phase); age of recipient (0 for <
20 years, 1 for 20 – 40 years, and 2 for > 40 years); sex
match (0 for all, except 1 for male recipient /female
donor); and time from diagnosis to transplantation (0
for < 12 months and 1 for > 12 months). No addition-
al prognostic factor was included.
Statistical analysis
The statistical analysis was performed based on
data of March 1st, 2003. The overall survival (OS), dis-
ease-free survival (DFS), transplant-related mortality
(TRM) and relapse incidence (RI) were estimated
using the Kaplan-Meier method and cumulative inci-
dence whenever appropriate. Cumulative incidence
was estimated using deaths unrelated to these causes
as competing risks. The EBMT risk score was ana-
EBMT risk scores for AHSCT in CML 
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Table 1. Distribution of patients according to gender and variables
of the EBMT risk score.
Status No. (%)
chronic phase 898 (83)
accelerated phase 146 (13)
blast crisis 40 (4)
Age (years)






HLA - full match 






<12 months 223 (21)
>12 months 861 (79)
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lyzed in a multivariate Cox proportional-hazards
regression model. S-Plus software version 2000 was
used.
Results
The characteristics of the patients according to the
variables used to calculate the risk score are shown in
Table 1. Eight hundred and ninety-eight patients
(83%) were in first chronic phase, 620 (57%) were
between 20 and 40 years old, 1,025 (94%) received
grafts from HLA identical siblings, and the interval
from diagnosis to transplant was greater than 12
months in 861 (79%) patients. In 283 (26%) cases a
male recipient had a female donor. Only 59 patients
(6%) received grafts from fullly matched unrelated
donors. After a median observation time of 15
months (range: 1-213), the OS, DFS, TRM and RI
were 49%, 50%, 45%, and 25%, respectively.
Although not incorporated in the EBMT score, it is
important to add that the source of stem cells was
bone marrow in 1,040 cases (95.9%), peripheral
blood progenitor cells in 40 (3.7%) and cord blood in
just 4 (0.4%). The conditioning regimen used in 86%
of the patients was busulfan (Bu) plus cyclophos-
phamide (CY), whereas 14% received a variety of
other regimens (TBI + CY; Bu + melphalan; TBI + flu-
darabine; fludarabine + melphalan). Graft-versus-
host disease (GVHD) prophylaxis in 94% of the
patients was  methotrexate plus cyclosporin A. The
OS rate varied according to the different periods,
being 56% for the years 1998-2003; 49% for 1993-
1997; 38% for 1988-1992 and 25% for 1983-1987,
showing a significant difference between the periods
(p=0.001). TRM was also significantly different
(p<0.001) between the periods being 39% for 1998-
2003; 45% for 1993-1997; 59% for 1988-1992 and
75% for 1983-1987.
Table 2 shows the distribution of patients stratified
according to EBMT risk score from 0 to 6. No
patients had a score of 7. One hundred and seventy-
nine patients (17%) had a score of 0 or 1, 397 (37%)
had a score of 2, 345 (32%) had a score of 3, 135
(12%) had a score of 4, and the remaining 28 patients
had a score of 5 or 6 (2%). The influence of risk score
on outcome of the 1,084 patients is presented in
Figure 1. Patients with a risk score of 3 or above had
higher TRM and lower OS and DFS. The relapse rate
was influenced by risk scores 5 and 6. In addition,
disease phase had a negative impact on all outcomes
(OS, DFS, TRM, and relapse) (Figure 2). The OS in
chronic phase, in accelerated phase and in blast crisis
was 55%, 28% and 14%, respectively (p<0.001).
Furthermore, OS for male recipients transplanted
from a female donor was 40% compared to 52% (p=
0.004). The patient’s age and time from diagnosis to
transplantation had no influence on the outcome.
Discussion
A large amount of data has been published in
recent years regarding the use of imatinib as front-
line therapy for CML. The high levels of hematolog-








Figure 1. Overall survival according to EBMT risk scores (A) and
transplant-related mortality (B).
Overall survival according to scores
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Score 5 or 6
A
B
Median Final value N Events pWald Relative risk
MedianFinal value N Events pWald Relative risk
58.5% 179 63 (ref) 1 (ref)
55.4% 397 163 0.24 (NS) 1.19 (0.89-1.59)
44.3% 345 174 0.004 1.53 (1.14-2.04)
36.2% 135 77 0.00032 (<0.001) 1.84 (1.32-2.57)
26.9% 28 19 0.00059 (<0.001) 2.46 (1.47-4.11)
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Score 5 or 6 8
35.2% 167 51 (ref) 1 (ref)
41% 378 144 0.13 (NS) 1.28 (0.93-1.76)
48.9% 309 138 0.0077 1.55 (1.12-2.13)
59.5% 123 66 0.00017 (<0.001) 2.01 (1.4-2.9)
59.4% 21 12 0.0091 2.31 (1.23-4.32)
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EBMT risk scores for AHSCT in CML 
ic and cytogenetic responses, combined with the
drug’s safety, have created a new and important par-
adigm in the treatment of CML. However, low lev-
els of molecular response (about 5% using the con-
ventional 400 mg/day dose12 up to about 30% using
a high dose of 800 mg/day,25 primary and acquired
resistance, and the possibility of progression, are
the most important concerns that must be analyzed
in order to be able to choose the most effective and
least toxic approach. Allogeneic HSCT has been
demonstrated to be able to cure CML in all clinical
phases. However, the risks of high morbidity and
TRM associated with acute and chronic GVHD
must be considered against the benefit of HSCT.
The present challenge is to identify subsets of
patients best suited to receive either imatinib or
HSCT. Based on our observation and important
papers published by Gratwohl23 and then by
Passweg,22 patients with low EBMT risk scores (0 to
2) may be the subgroup best treated with HSCT. In
fact, patients with a risk score of 3 or above who are
treated with HSCT have a low OS and DFS and
high TRM and relapse rate. In addition, the status of
disease at transplantation is a powerful predictor of
outcome. Patients in accelerated phase or in blast
crisis have a very bad prognosis. Although HSCT
might be the only treatment able to cure patients in
advanced phase, only a few patients in this sub-
group achieve a long and stable remission or defini-
tive cure. There are currently two important points
that need to be examined: (i) the increase in risk if
imatinib is given first and transplants are performed
only at progression or if imatinib fails; (ii) a defini-
tion of a cohort of patients with such a low chance
of success with HSCT that it is not justifiable to use
the limited resources.
This study was intended to present the results of
CML patients treated with HSCT in a developing
country and validate the EBMT risk score in the
same context. The patients in the study represent
Figure 2. Overall survival (A), disease-free survival (B), transplant-related mortality (C) and relapse incidence (D) according to disease status. 
A B
C DTRM according to status
Relapse according to status
Overall survival according to status Disease-free survival according to status
Chronic phase NA 54.7% 898 366 (ref) 1 (ref)
Accelerate phase 11 27.7% 146 96 2.5e-007 (<0.001) 81 (1.44-2.66)
Blast crisis 5 14% 40 34 2.9e-010 (<0.001) 11 (2.18-4.42)
Chronic phase NA 55.4% 782 299 (ref) 1 (ref)
Accelerate phase 9 26.8% 122 826.5e-011(<0.0012) 26 (1.77-2.89)
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Chronic phase NA 41.8% 858 326 (ref) 1 (ref)
Accelerate phase 15 61% 113 63 0.00035 (<0.001) 1.64 (1.25-2.14)
Blast crisis 4 81,5% 27 22 6.9e-008 (<0.001) 3.29 (2.13-5.07)
Chronic phase NA 16.8% 898 74 (ref) 1 (ref)
Accelerate phase NA 45.5% 146 40 6.7e-0.15 (<0.0014) 4.65 (3.16-6.84)
Blast crisis 11 60.7% 40 14 1.8e-0.15 (<0.001) 0.42 (5.86-18.56)
p=2.3e-007 (< 0.001)
(Likelihood ratio test) 
p=0 (< 0.001)
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Figure 3. Overall survival (A) and TRM (B) according to period of time.
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